Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807050 | 1.00 | MAPT (0.41) | MAPTTRPM8CYP1A2PTGS2CYP2C9 | |
| SCHEMBL19899702 | 0.80 | ALDH1A1 (0.39) | MAPTCYP1A2PTGS2TSHRL3MBTL1 | |
| SCHEMBL16264455 | 0.77 | CYP2C9 (0.58) | MAPTCYP1A2CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL19899747 | 0.77 | HRH3 (0.37) | MAPTALDH1A1NPSR1SMN1; SMN2GAA | |
| SCHEMBL31493447 | 0.77 | HRH3 (0.37) | MAPTALDH1A1NPSR1SMN1; SMN2GAA | |
| SCHEMBL23291972 | 0.76 | ALDH1A1 (0.47) | MAPTTRPM8CYP1A2PTGS2CYP2C9 | |
| SCHEMBL31207823 | 0.75 | MAPT (0.48) | MAPTTRPM8CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL25243517 | 0.75 | MAPT (0.48) | MAPTTRPM8CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL30881402 | 0.75 | MAPT (0.41) | MAPTTRPM8ALDH1A1NPSR1NPC1 | |
| SCHEMBL27243736 | 0.75 | MAPT (0.41) | MAPTTRPM8ALDH1A1NPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562018-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026061-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3504211-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | Eli Lilly and Company (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2018039062-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | BACE1, BACE2, PSEN1 | MAPT 17/4885TRPM8 2866/4885CYP1A2 2113/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | MAPT 3970/4885TRPM8 357/4885CYP1A2 1690/4885 |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | MAPT 17/4885TRPM8 2866/4885CYP1A2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.